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 Introduction 
 Cushing’s syndrome (CS) is traditionally divided into 
adrenocorticotropin (ACTH)-dependent CS and ACTH-
independent CS. ACTH-dependent CS is usually caused 
by a corticotropic pituitary adenoma and rarely by ecto-
pic ACTH production by a neuroendocrine tumor. 
ACTH-independent CS is caused by an adrenal adenoma, 
adrenal carcinoma or bilateral adrenal hyperplasia. At 
present, surgery is the first-line treatment modality for 
CS, irrespective of its cause, in order to achieve bio-
chemical cure  [1] . However, if surgery fails or is contrain-
dicated, hypercortisolism is treated medically. Medical 
treatment of CS can be divided into three groups: (1) ad-
renal-blocking drugs; (2) neuromodulatory drugs, e.g. 
somatostatin analogs, dopamine agonists, and (3) gluco-
corticoid receptor-blocking agents, e.g. mifepristone  [1, 
2] . Among these drugs, adrenal-blocking drugs are wide-
ly used and their indications, efficacy and adverse event 
profiles are discussed in this overview.
 Indications for Medical Therapy 
 Depending on the cause of CS various indications 
 exist for medical therapy to treat hypercortisolism ( ta-
ble 1 ).
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 Abstract 
 Cushing’s syndrome is associated with serious morbidity 
and increased mortality. Irrespective of its cause, i.e. a pitu-
itary adenoma, ectopic ACTH production or an adrenal neo-
plasia, Cushing’s syndrome is primarily treated surgically. 
However, when surgery is unsuccessful or contraindicated, 
medical therapy is needed to treat hypercortisolism. The 
spectrum of available drugs includes adrenal-blocking 
agents, neuromodulatory drugs and glucocorticoid receptor 
antagonists. Adrenal blocking drugs suppress adrenal corti-
sol production via inhibition of steroidogenic enzymes. Ke-
toconazole and metyrapone are most frequently used for 
this purpose, but chronic treatment with these drugs can be 
limited by side effects like hepatotoxicity (ketoconazole) and 
increased androgen and mineralocorticoid production (me-
tyrapone). Etomidate can be used to rapidly reverse cortisol 
excess in patients with acute complications of (severe) hy-
percortisolism like psychosis. In Cushing’s disease, combina-
tion therapy with drugs that target the corticotropic adeno-
ma, i.e. the universal somatostatin analogue pasireotide 
and/or the dopamine agonist cabergoline, and low-dose ke-
toconazole seems a rational approach to achieve biochemi-
cal control.  Copyright © 2010 S. Karger AG, Basel 
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 Pituitary-Dependent CS 
 In patients with pituitary-dependent CS, medical 
therapy is applied in several centers as pretreatment be-
fore pituitary surgery in order to decrease perioperative 
complications due to hypercortisolism. With transsphe-
noidal adenomectomy, biochemical remission is achieved 
in 60–80% of patients, in particular in patients with mi-
croadenomas  [1, 3, 4] . However, success rates are consid-
erably lower in patients with macroadenomas, invisible 
adenomas or adenomas with unfavorable localization 
such as the parasellar region. In addition, in the long 
term, recurrences do occur in up to 20% of patients  [1, 
3–5] . These patients are frequently treated with radio-
therapy to induce definitive remission. However, radio-
therapy has a slow onset of action, resulting in exposure 
of patients to the deteriorating effects of cortisol excess 
during several years  [6] .
 Persistent hypercortisolism is associated with in-
creased morbidity and mortality. Apart from the clinical 
features of CS that severely impair quality of life, uncon-
trolled hypercortisolism increases the risk on infectious, 
thromboembolic and cardiovascular disease  [7] . Mortal-
ity is increased in CS, in particular in those patients with 
persistent hypercortisolism  [8] . This underscores the im-
portance of reversal of cortisol excess in CS. Therefore, 
indications of medical therapy for pituitary-dependent 
CS include pre-surgical treatment, although controlled 
studies on efficacy are lacking, persistent or recurrent hy-
percortisolism after pituitary surgery and to overcome 
the period after which radiotherapy becomes effective. 
Primary medical therapy can be considered in patients 
with a nonvisible adenoma and in patients with a high 
operation risk due to high age and/or significant comor-
bidity.
 Ectopic ACTH Syndrome 
 Cushing’s syndrome caused by ectopic ACTH pro-
duction is frequently accompanied by acute complica-
tions of hypercortisolism due to the severity of cortisol 
excess. This includes symptoms like hypertension, hypo-
kalemia and edema due to mineralocorticoid effects of 
high cortisol levels, psychosis and (opportunistic) infec-
tions. In these conditions, hypercortisolism needs to be 
treated rapidly, either medically or by bilateral adrenal-
ectomy  [7] .
 Patients with metastatic disease and ectopic ACTH 
production cannot be cured surgically and in these pa-
tients medical therapy, or ultimately bi-aderenalectomy, 
is indicated to treat hypercortisolism, next to tumor-di-
rected therapy, i.e. chemo- or radiotherapy.
 Adrenal Cushing’s Syndrome 
 Adrenal causes of CS in which medical therapy can be 
indicated are bilateral adrenal hyperplasia and adrenal 
carcinoma. In patients with bilateral adrenal hyperplasia, 
cortisol production is frequently regulated by ectopic 
hormone receptor expression, e.g. vasopressin receptor, 
luteinizing hormone receptor, and in some patients cor-
tisol production can be normalized by blockade of the 
ectopic receptor or by inhibition of the production of its 
endogenous ligand  [9] . Otherwise, these patients are usu-
ally treated by bilateral adrenalectomy.
 Patients with unresectable or metastasized corti-
sol-producing adrenal carcinoma are treated with cor-
tisol-lowering agents next to tumor-directed therapy to 
treat symptoms and prevent complications of cortisol 
excess.
 Adrenal-Blocking Drugs 
Several adrenal-blocking drugs can be used to treat 
hypercortisolism in CS (table 2) which are discussed be-
low. However, it should be noted that none of these drugs 
has officially been approved for the treatment of CS. In 
addition, most studies that report on the therapeutic ef-
fects of these drugs show retrospective data in small pa-
tient numbers.
Table 1.  Possible indications for medical therapy for Cushing’s 
syndrome
Type of Cushing’s 
syndrome
Indication
Pituitary-dependent 
Cushing’s syndrome
Pretreatment before pituitary surgery
Acute complications of hypercortisolism
Persistent hypercortisolism after pituitary 
surgery
Nonvisible adenomas
High operation risk
Ectopic ACTH 
syndrome
Acute complications of hypercortisolism
Unresectable or metastasized tumors 
High operation risk
Adrenal Cushing’s 
syndrome
Acute complications of hypercortisolism
Unresectable or metastasized adrenal
carcinoma
Ectopic hormone receptor expression
High operation risk
 Adrenal-Blocking Drugs in Cushing’s 
Syndrome 
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 Aminoglutethimide 
 Aminoglutethimide is an anticonvulsant agent that 
also suppresses adrenal steroid production by inhibition 
of cholesterol side-chain cleavage and the steroidogenic 
enzymes 11  -hydroxylase and 18-hydroxylase  [2] . Ami-
noglutethimide has been used to decrease cortisol pro-
duction in CS in the past, although with an unfavorable 
adverse event profile, but at present, the drug is no longer 
available.
 Mitotane 
 Mitotane, o,p-DDD, is an adrenolytic agent that is 
used primarily to treat adrenal carcinoma. Apart from 
suppression of cell growth, mitotane inhibits cholesterol 
side-chain cleavage and 11  -hydroxylase resulting in de-
creased cortisol production  [10] . Mitotane, in a dose up 
to 6 g/day, can be effective in the treatment of ACTH-
dependent CS  [11] ; however, it has a slow onset of action 
and serum levels of mitotane should be monitored to 
achieve therapeutic concentrations and to prevent toxic-
ity. Mitotane has serious gastrointestinal, neurological 
and hepatic side effects. In addition, mitotane can induce 
adrenal insufficiency, hypercholesterolemia and altera-
tions in hormone-binding globulins  [2] . Considering 
these adverse events, mitotane is not very suitable for 
chronic treatment of hypercortisolism in CS except for 
cortisol-producing adrenal carcinomas.
 Etomidate 
 The anesthetic drug etomidate, an imidazole deriva-
tive, suppresses steroidogenesis by inhibition of choles-
terol side-chain cleavage and the enzymes 17-hydroxy-
lase, 11  -hydroxylase and C17–20 lyase  [12] . Etodimate 
has a rapid onset of action and is particularly useful in 
patients with acute and/or life threatening complications 
of CS, e.g. psychosis and severe hypertension, in an ICU 
setting  [13] . Generally, these are patients with ectopic 
ACTH production and overwhelming cortisol produc-
tion, but cases with patients with Cushing’s disease have 
also been reported  [2] . Etomidate is given parenterally at 
a dose of between 0.03 and 0.3 mg/kg/h  [1] .
 Metyrapone 
 Metyrapone blocks the last step of cortisol synthesis 
by inhibition of 11  -hydroxylase  [14] and can decrease 
cortisol production in patients with adrenal tumors, ec-
topic ACTH production and Cushing’s disease  [15] . Ef-
fective dosages of metyrapone vary between 500 and 
6,000 mg/day  [1, 2] . Patients should be carefully moni-
tored for the development of hypocortisolism. A poten-
tial disadvantage of metyrapone treatment of Cushing’s 
disease is the occurrence of a compensatory increase in 
ACTH production resulting from a decrease in cortisol-
mediated negative feedback on the corticotropic adeno-
ma  [15] . This, in turn, can lead to an increased adrenal 
production of cortisol, but also of androgens and miner-
alocorticoid precursors. Although an escape of cortisol 
levels is infrequently observed during metyrapone treat-
ment, hirsutism, acne and mineralocorticoid effects (hy-
pertension, hypokalemia and edema) can limit prolonged 
treatment with metyrapone  [1, 2, 15] . In several countries 
metyrapone is not available commercially.
 Ketoconazole 
 Ketoconazole, an imidazole derivative, is an antifun-
gal agent that, in higher dosages, reduces adrenal steroid 
production via inhibition of multiple steroidogenic en-
zymes, e.g. 11  -hydroxylase, 17-hydroxylase and 18-hy-
droxylase  [16, 17] . In a dose range between 400 and 1,200 
mg/day, ketoconazole can decrease cortisol production in 
patients with CS of various etiology  [1, 2, 17–20] . The ma-
jor side effect of ketoconazole is hepatotoxicity and liver 
function should be monitored carefully during treat-
ment. In addition, ketoconazole can cause hypogonadism 
in men and gastrointestinal complaints. No prospective 
studies with ketoconazole monotherapy have been per-
Table 2.  Adrenal-blocking drugs
Drug Mechanism Dose Efficacy Adverse events
Mitotane adrenolytic effects 0.5–8 g/day 880% neurological, gastrointestinal
Etomidate inhibition of SE 0.03–0.3 mg/kg/h unknown hypocortisolism
Metyrapone inhibition of SE 0.5–6 g/day 875% hypertension, acne, hirsutism
Ketoconazole inhibition of SE 400–1,200 mg/day 870% hepatotoxicity, gastrointestinal, hypogonadism
S E = Steroidogenic enzymes.
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formed. Therefore, efficacy data are only available from 
retrospective studies, mostly with small patient numbers. 
Recently, Castinetti et al.  [20] reported that ketoconazole 
induced biochemical remission in 50% of patients with 
Cushing’s disease. Taking all studies together, ketocon-
azole has an efficacy of approximately 70%  [20] . Studies 
are, however, difficult to compare with respect to patient 
selection, treatment duration, pretreatment with radio-
therapy, etc.
 Apart from adrenal blocking effects, ketoconazole 
may also have direct effects on corticotropic tumor cells 
in patients with Cushing’s disease. Stalla et al. [21] have 
shown that ketoconazole inhibits both basal and CRF-
stimulated ACTH production by rat anterior pituitary 
cells. We have recently found that ketoconazole suppress-
es ACTH production by both mouse AtT20 and human 
corticotropic tumor cells. In addition, ketoconazole in-
hibited cell growth, in part by the induction of apoptosis. 
Interestingly, the effects on ACTH secretion and cell 
growth were potentiated by the universal somatostatin 
analog pasireotide [unpubl. results]. These effects may 
explain the absence of a compensatory rise in ACTH lev-
els in patients with Cushing’s disease during prolonged 
treatment with ketoconazole  [18] , which contrasts to the 
observed ACTH increase during chronic treatment with 
metyrapone  [15] .
 Combination Therapy 
 Currently, no medical monotherapy is available for the 
treatment of CS that couples a maximum efficacy to a 
minimum of toxicity. In addition, for Cushing’s disease, 
the most prevalent form of CS, there is a clear need for 
tumor-directed therapy. Somatostatin receptor subtype 
(sst) 5 and dopamine receptor subtype 2 (D 2 ) are poten-
tial therapeutic targets on corticotropic tumor cells  [22] . 
In a short-term trial with pasireotide, a novel somatosta-
tin analog with high affinity for sst 1,2,3 and sst 5 , normal-
ization of urinary free cortisol (UFC) levels was achieved 
in 17% of patients  [23] . Treatment with the D 2 agonist ca-
bergoline resulted in long-term control in 40% of patients 
 [24] . We recently performed a study with pasireotide 
mono- or combination therapy with cabergoline and low-
dose ketoconazole during 80 days  [25] . Seventeen patients 
with Cushing’s disease were treated in a stepwise ap-
proach with pasireotide as initial treatment modality 
which was extended with cabergoline and ketoconazole 
after 4 and 8 weeks, respectively, according to UFC levels. 
With this approach, biochemical remission was achieved 
in 90% of patients, i.e. in 29% (5/17) with pasireotide 
monotherapy, in an additional 24% (4/17) by addition of 
cabergoline to pasireotide and in another 35% (6/17) by 
triple therapy with pasireotide, cabergoline and ketocon-
azole. Pivonello et al.  [24] also found beneficial effects of 
the addition of low-dose ketoconazole in patients who 
were partially responsive to cabergoline [unpubl. results]. 
Combination therapy with drugs that have additive or 
potentiating effects seems a rational approach to treat CS 
and may allow for lower dosages of drugs with serious 
adverse events like ketoconazole.
 Conclusions 
 Medical therapy has an important role in the treat-
ment of CS when surgery is unsuccessful or not indicated. 
The increased morbidity and mortality of uncontrolled 
CS highlights the importance of rapid reversal of hyper-
cortisolism. Inhibition of adrenal steroid synthesis with 
adrenal-blocking drugs can be effective and in this re-
spect metyrapone and ketoconazole are most frequently 
used. Long-term use of these drugs can, however, be lim-
ited by side effects. Etomidate can be useful in patients 
with acute complications of severe hypercortisolism. In 
Cushing’s disease, combination therapy of (low-dose) ke-
toconazole with pasireotide and/or cabergoline is a prom-
ising treatment modality. Prospective, long-term studies 
are needed to establish efficacy, in terms of reversal of 
increased morbidity and mortality, and safety of medical 
therapy for CS.
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